ESTRO meets Asia 2024 - Abstract Book

S168

Interdisciplinary – Head & neck

ESTRO meets Asia 2024

loss (all grade: 34.2%, ≥grade III: 4.9%) , anorexia (all grade: 31.8%, ≥grade III: 5.7%), rash (all grade: 29.4%, ≥grade III: 19.2%) and headache(all grade: 29.0%, ≥grade III: 10.7%).

Conclusion:

The findings of this study suggest that MKIs have a better therapeutic efficacy than other-target drugs in patients with R/M ACC. Future studies are warranted to verify the synergistic role of the combination strategy of MKIs plus ICIs, given the limited number of studies on this topic conducted and published to date. PROSPERO Registration Number: CRD42022376157; https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022376157

Keywords: adenoid cystic carcinoma, targeted therapy;

References:

[1] Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012 Feb 1;12:9.

[2] Combescure C, Foucher Y, Jackson D. Meta-analysis of single-arm survival studies: a distribution-free approach for estimating summary survival curves with random effects. Stat Med. 2014 Jul 10;33(15):2521-37.

164

Digital Poster

A Predictive Nomogram Model for Head and Neck Adenoid Cystic Carcinoma

Siqi Xu, Ying Li, Yuhao Lin, Sufang Qiu

Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China

Purpose/Objective:

To develop and validate a predictive nomogram with clinical variables for guiding personalized therapy selection in adenoid cystic carcinoma of the head and neck (ACCHN).